Brind.
  1. AstraZeneca announced a joint development and commercialization partnership with HUTCHMED, a company based in China with operations in Shanghai.

AstraZeneca paid a milestone payment to Hutchison MediPharma Limited on August 7, 2025.

1 report, 1 independent Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AstraZeneca paid a milestone payment to Hutchison MediPharma Limited on August 7, 2025.

Who's involved

What this event is mainly about
Hutchison MediPharma LimitedAstraZeneca

Keep exploring

Part of

AstraZeneca announced a joint development and commercialization partnership with HUTCHMED, a company based in China with operations in Shanghai. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireHUTCHMED Reports 2025 Interim Results — Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial di